Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Dihexa peptide: does it work, is it legal, and what does it cost?

Oral lab-made relative of the brain peptide angiotensin IV: rat memory data from one lab, a retracted mechanism paper, no human trials, no FDA approval.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about Dihexa
Does it work in people?Evidence: Animal-only evidence

No randomized human trial of this peptide; the grade rests on animal and lab studies. See the evidence

Is it legal?Regulatory: Nomination withdrawn

Not FDA approved and not on FDA's list of substances pharmacies may compound (the 503A bulks list), so a pharmacy has no federal basis to compound it. [4] [11] See legal status

What does it cost?Not available through licensed channels.
Side effects?No human safety data of any kind published. No animal toxicology study published. Theoretical concern that potentiating HGF/c-Met signaling could promote tumor growth, because c-Met is an oncogene targeted by several cancer drugs (not tested for dihexa). See side effects and interactions
Tested athlete?WADA: WADA prohibited

What is Dihexa?

Dihexa is a small synthetic peptide derived from angiotensin IV, a breakdown product of the blood pressure hormone angiotensin II, and designed at Washington State University to cross the blood brain barrier (the filter that keeps most substances out of the brain) and promote synapse formation (new connections between nerve cells). Its entire evidence base is rat behavior and cell culture (cells grown in a dish) from the inventing laboratory: it reversed scopolamine induced memory deficits in rats in a 2013 paper that now carries an expression of concern (a journal warning about its reliability), and the 2014 paper proposing its hepatocyte growth factor mechanism was retracted in 2025. No human trial has been published, it is not FDA approved, and it is not available through any licensed channel in the United States.

Dihexa is a synthetic angiotensin IV derived oligopeptide (hexanoyl capped Tyr-Ile with an aminohexanoic amide tail), hepatocyte growth factor/c-Met potentiator. It is also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, PNB-0408, Dihexa peptide, Angiotensin IV analog dihexa.

How does it work?

Dihexa was reported to bind hepatocyte growth factor (HGF) with high affinity and to potentiate signaling through the c-Met receptor, which in turn drives dendritic spine growth and synaptogenesis in cultured hippocampal neurons. The 2014 paper that established this mechanism was retracted by the journal in 2025, and the 2013 paper describing dihexa's design and rat memory effects carries a 2021 expression of concern, so the mechanism should be treated as unconfirmed. Dihexa is orally active and blood brain barrier permeant in rats according to the developers.

Key facts
ClusterCognitive and neuroprotective
RoutesOral (rat studies; sold as capsules or powder); Intraperitoneal injection (rat studies); Transdermal and subcutaneous products exist without absorption data
Conditions studiedCognitive decline and nootropic use
Recordv3, reviewed, verified Sep 29, 2026

Dihexa benefits: what the evidence shows

Evidence: Animal-only evidenceGrade assigned per the methodology.

One laboratory reports that dihexa reverses scopolamine induced deficits in the Morris water maze in rats, improves performance in aged rats, and increases hippocampal spine density in culture. Independent replication has not been published, the mechanism paper was retracted, and the design paper carries an expression of concern. No human pharmacokinetic, safety, or efficacy study exists as of the last verification date, so the grade is animal-only with a data integrity caveat.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials0n/a
Human observational studies0n/a
Animal studies2n/a
All indexed studies2n/a

Human evidence

No human study of any kind identified. No indexed human trial, case series, or safety report has been published. The developers' proposal to advance an angiotensin IV analog toward Alzheimer's disease trials has not resulted in a registered human trial with published results.

Animal evidence

McCoy et al. (2013) modified the N-terminal tripeptide of norleucine-1-angiotensin IV to produce dihexa, an orally active analog that reversed scopolamine induced deficits in Morris water maze performance in rats, improved spatial memory in aged rats, and increased hippocampal synaptogenesis. Benoist et al. (2014, retracted 2025) reported that dihexa's procognitive and synaptogenic effects in rats and cultured neurons depend on HGF/c-Met signaling. No toxicology study in animals has been published, and no group outside the inventing laboratory has replicated the memory findings.

Key studies

Indexed studies of Dihexa
StudyDesign and populationOutcomeGrade
Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents2013 PMID 23055539Rat behavioral pharmacology (scopolamine induced amnesia and aged rat Morris water maze) plus hippocampal neuron culture; carries a 2021 expression of concernRats and cultured rat hippocampal neuronsDihexa, an orally active blood brain barrier permeant analog, reversed scopolamine induced water maze deficits, improved aged rat performance, and increased synaptogenesis in cultureEvidence: Animal-only evidence
The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system (retracted 2025)2014 PMID 25187433Mechanistic study in cultured neurons and rats; retracted by the journal in April 2025Rats and cultured rat hippocampal neuronsReported that dihexa binds HGF, potentiates c-Met phosphorylation, and that an HGF antagonist blocked its water maze effects; the article was retracted so these findings are not reliableEvidence: Animal-only evidence

Conditions studied

Conditions with evidence for Dihexa
ConditionGradeNote
Cognitive decline and nootropic useEvidence: Animal-only evidenceRodent studies only; no human safety data.

Is Dihexa legal in the United States?

Regulatory: Nomination withdrawnWADA: WADA prohibited

FDA and compounding status

Dihexa has never been approved by FDA for any use. It was previously in 503A Category 2. FDA now lists dihexa acetate among nominations withdrawn by the nominators and notes that it has found no human exposure data. That places it in no 503A category and outside FDA's interim enforcement policy. FDA has said it will ask the Pharmacy Compounding Advisory Committee to consider dihexa acetate for the 503A bulks list at a meeting planned before the end of February 2027. As of the last verification date, no meeting date had been announced. Because it is not on that list, a 503A pharmacy has no federal basis to compound it, and no 503B pathway has been identified.

WADA status

WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.

Regulatory timeline

  1. FDA

    FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

    FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

  2. FDA

    FDA places a batch of nominated peptides in 503A Category 2

    In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.

Full tracker for Dihexa or the category-wide tracker.

Email me when Dihexa's status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of Dihexa used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Not established in human literature. Rat studies gave dihexa orally or by injection in scopolamine and aged rat memory models; no human pharmacokinetic or dose finding study has been published and no dose can be inferred from the animal work.

Routes reported

Routes of administration reported for Dihexa
#Route
1Oral (rat studies; sold as capsules or powder)
2Intraperitoneal injection (rat studies)
3Transdermal and subcutaneous products exist without absorption data

Dihexa side effects

Side effects

Side effects reported for Dihexa
#Reported side effect
1No human safety data of any kind published
2No animal toxicology study published
3Theoretical concern that potentiating HGF/c-Met signaling could promote tumor growth, because c-Met is an oncogene targeted by several cancer drugs (not tested for dihexa)
4Anecdotal reports of headache and fatigue are unverified

Interactions

Interactions reported for Dihexa
#Interaction
1No formal interaction studies exist
2Theoretical opposition to c-Met inhibitors used in oncology (for example capmatinib, tepotinib, crizotinib), since dihexa is proposed to activate the same receptor
3Theoretical interaction with angiotensin system drugs given its angiotensin IV origin (not tested)

Contraindications

Contraindications for Dihexa
#Contraindication
1Active cancer or history of cancer (c-Met is a well established oncogene, and dihexa is proposed to potentiate its signaling)
2Pregnancy and breastfeeding (no data)
3Competitive athletes subject to WADA testing (prohibited at all times under S0)

How do people access Dihexa legally?

Typical cost: Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.

Access options

  • Not available

    Not legally available for human use in the United States: no FDA approved product and no identified compounding pathway.

  • Not available

    Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

Compare Dihexa

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. PeptideAgent has not found an FDA warning letter or review that names dihexa. [8] [9] [10]

Being offered does not change the legal status of dihexa. Dihexa is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [4] [11]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [8] [11] [12] [13] [14] [15]

What that means for you

  • A pharmacy that compounds dihexa is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [8] [12]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [15]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [16]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [17] [18]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [11]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, dihexa is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [6]

If you're going ahead anyway

These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound dihexa, with or without a prescription. [4]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [19] [20] [21]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [10] [21] [22]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [15] [23] [24] [25] [26] [27]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [15]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [19]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [10]
  • Pharmacy: Is this made for me on a prescription written in my name? [22]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [10] [21]
  • Prescriber: What is the legal basis for a pharmacy to compound dihexa? Is it FDA approved or on the 503A bulks list? [4] [15]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [10]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [16]

Frequently asked questions

What is dihexa?

Dihexa is a small synthetic peptide derived from angiotensin IV, a breakdown product of the blood pressure hormone angiotensin II, designed at Washington State University to cross the blood brain barrier (the filter that keeps most substances out of the brain) and promote new synapse formation (connections between nerve cells). It is marketed as a nootropic (a supposed memory or focus enhancer), but all of its evidence comes from rats and cell culture (cells grown in a dish) in the inventing laboratory, the paper proposing its mechanism was retracted in 2025, and it has never been tested in people or approved by FDA. [1] [2]

Is dihexa legal in the United States?

It is not an FDA approved drug and has never been reviewed by FDA. It was named on the FDA 503A Category 2 list in 2023; FDA now lists it as a withdrawn nomination (off Category 2 but not on the 503A bulks list), and it was not among the peptides FDA presented to the committee in July 2026, so a 503A pharmacy has no federal basis to compound it. Possessing it is not a crime, but no licensed provider or pharmacy can lawfully supply it for human use, and research chemical products sold for human use are unapproved drugs. [4] [5] [7]

Does dihexa work for memory or Alzheimer's disease?

In rats, the inventing laboratory reported that dihexa reversed scopolamine induced memory deficits and improved spatial memory in aged animals. In humans, there is no evidence at all: no trial, case series, or safety study has been published. The 2014 paper that explained how dihexa is supposed to work was retracted in 2025 and the 2013 design paper carries an expression of concern, so even the animal claims should be read cautiously. PeptideAgent grades the evidence animal-only. [1] [2]

What are the side effects of dihexa?

Nobody knows, because no human safety data and no animal toxicology study have been published. The most discussed theoretical risk is cancer: dihexa is proposed to potentiate the HGF/c-Met pathway, and c-Met is an oncogene that several approved cancer drugs are designed to block. Reports of headache or fatigue from users are anecdotal and unverified. [2] [3]

Why was the dihexa mechanism paper retracted?

The 2014 Journal of Pharmacology and Experimental Therapeutics paper by Benoist and colleagues, which reported that dihexa binds hepatocyte growth factor and acts through c-Met, received an expression of concern from the journal in 2021 and was retracted in April 2025. The companion 2013 paper describing dihexa's synthesis and rat memory effects received an expression of concern at the same time. PeptideAgent lists both so readers can see the record, but treats the mechanism as unconfirmed. [1] [2]

How is dihexa taken?

In the rat studies it was given orally or by injection. Products marketed to people are usually oral capsules, powders, or transdermal preparations. No human pharmacokinetic study exists, so there is no basis for any human dose or route, and none of the marketed forms has absorption data. [1]

How much does dihexa cost?

It is not available through any licensed channel, so there is no pharmacy or telehealth price. Products sold as research chemicals for human use are unapproved drugs and their identity and purity are not verified. [4] [7]

Is dihexa banned by WADA?

Yes. Dihexa has no approval from any governmental health authority for human use, so it falls under section S0 (non-approved substances) of the WADA Prohibited List and is prohibited at all times, in and out of competition. [6]

Dihexa vs semax: which has better evidence for cognition?

Semax has more human data. Semax is a registered prescription drug in Russia with decades of clinical use and Russian trial reports, and news reports said the committee voted to recommend listing it in July 2026, but FDA's own briefing recommended against listing, and FDA has not posted the vote or minutes. Dihexa has no human data of any kind, a retracted mechanism paper, and no identified lawful supply channel in the United States. Neither has an indexed randomized trial that meets Western regulatory standards. [1] [5]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]McCoy AT et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther 2013 (expression of concern 2021)PubMed 23055539, 2013
  2. [2]Benoist CC et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther 2014 (retracted April 2025)PubMed 25187433, 2014
  3. [3]Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer's disease. J Alzheimers Dis 2015 (review by the developers)PubMed 25649658, 2015
  4. [4]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  5. [5]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  6. [6]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  7. [7]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  8. [8]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
  9. [9]FDA warning letter 594743, April 1, 2020, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2020
  10. [10]FDA to telehealth companies: What to know when promoting compounded drugsFDA, 2026

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 29). Dihexa: evidence, legality, and access. https://peptideagent.ai/peptides/dihexa
HTML link
<a href="https://peptideagent.ai/peptides/dihexa">Dihexa: evidence, legality, and access</a>, PeptideAgent, updated September 29, 2026.